The Effects of Escitalopram on Cytokines (BAFH)

Beitou Armed Forces Hospital, Taipei, Taiwan

Status: Unknown

Conditions: Depression

Treatments: Drug: Escitalopram

Study type: Interventional

Funder types: Other

Identifiers

NCT01587326

BAFH-101-05

BAFH (Other Identifier)

Details and patient eligibility

About

The association of cytokines with escitalopram has not been investigated in patients with major depressive disorder (MDD). Hence, the investigators will examine this association.

Full description

In addition to serotonin, inflammatory process has been suggested in the development of major depressive disorder (MDD) and in its associated treatment. Escitalopram is an antidepressant that has been widely used in patients with MDD because of the promising results. The association of cytokines with escitalopram has not been investigated in patients with MDD. Hence, the investigators will examine this association.

Enrollment: 25 estimated patients

Sex: All

Ages: 20 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. DSM-IV-defined Major depressive disorder, single episode
2. Age 20-65
3. Drug-naive
4. Hamilton Depression Rating Scale exceeding 14 scores

Exclusion criteria

1. Major medical disorders
2. Substance use
3. Pregnant
4. Allergy to escitalopram

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

25 participants in 1 patient group

Escitalopram

Experimental group

Description:

Escitalopram 10 mg/d to 20 mg/d

Treatment:

Drug: Escitalopram